biostudies-literatureUnknown97(11)Vantyghem MC<h4>Context</h4>For the last 10 yr, continuous glucose monitoring (CGM) has brought up new insights into the accuracy of blood glucose analysis.<h4>Objective</h4>Our objective was to determine how islet graft function was able to influence the various components of dysglycemia after islet transplantation (IT).<h4>Design and setting</h4>We conducted a single-arm open-labeled study with a 3-yr follow-up in a referral center (ClinicalTrial.gov identifiers NCT00446264 and NCT01123187).<h4>Patients</h4>Twenty-three consecutive patients with type 1 diabetes (14 islet alone, nine islet after kidney) received IT within 3 months using the Edmonton protocol.<h4>Intervention</h4>INTERVENTION included 72-h CGM before and 3, 6, 9, 12, 24, and 36 months after transplantation.<h4>Main outcome measure</h4The Journal of clinical endocrinology and metabolismE2078-83https://www.ebi.ac.uk/biostudies/studies/S-EPMC3485599biostudies-literatureContinuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).PMC3485599Defrance FKerr-Conte JRaverdy VCaiazzo RGmyr VHazzan MVantyghem MCBalavoine ASArnalsteen LNoel CPattou FfalseContinuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).<h4>Context</h4>For the last 10 yr, continuous glucose monitoring (CGM) has brought up new insights into the accuracy of blood glucose analysis.<h4>Objective</h4>Our objective was to determine how islet graft function was able to influence the various components of dysglycemia after islet transplantation (IT).<h4>Design and setting</h4>We conducted a single-arm open-labeled study with a 3-yr follow-up in a referral center (ClinicalTrial.gov identifiers NCT00446264 and NCT01123187).<h4>Patients</h4>Twenty-three consecutive patients with type 1 diabetes (14 islet alone, nine islet after kidney) received IT within 3 months using the Edmonton protocol.<h4>Intervention</h4>INTERVENTION included 72-h CGM before and 3, 6, 9, 12, 24, and 36 months after transplantation.<h4>Main outcome measure</h42012-01-01T00:00:00Z2012 Nov2025-06-01T00:11:17.836Z2025-06-01T00:11:17.836ZS-EPMC34855992299614410.1210/jc.2012-2115